ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2343

Risk of Arrhythmias Following IL-17 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Abstract Number: 2344

Impact of Bimekizumab Use in Spondyloarthritis and Psoriatic Arthritis: Persistence Study in Routine Clinical Practice in Spain (BIMPACT study)
Abstract Number: 2345

Biological Sex-Related Differences in Radiographic Progression and Relationship with Early Clinical Response: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo‑Controlled Study in Biologic-Naive Participants with Active Psoriatic Arthritis Treated with Guselkumab
Abstract Number: 2346

Back in Action: Six Months of Biological Therapy Improve Sexual Function in Men with Ankylosing Spondylitis
Abstract Number: 2347

Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension
Abstract Number: 2348

Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.
Abstract Number: 2349

Classification of “Difficult-to-Manage Axial Spondyloarthritis”: A Real-World Cohort Study Evaluating the ASAS 2024 Criteria Over Time
Abstract Number: 2350

Multicenter study on the use of Upadacitinib: sex specific results in Spondyloarthritis
Abstract Number: 2351

Modulation of Tyrosine Kinase 2- and Disease-Related Biomarkers by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent Tyrosine Kinase 2 Inhibitor, Is Associated With Clinical Response in Patients with Active Psoriatic Arthritis
Abstract Number: 2352

Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update
Abstract Number: 2353

Efficacy of Vunakizumab in Reducing Pain in Ankylosing Spondylitis: A Post-Hoc Analysis of a Phase 2/3 Clinical Trial
Abstract Number: 2354

ChatGPT or SPSS? A comparison between AI-based and Traditional Statistical Analysis of Longitudinal Inflammatory Marker Data in Spondyloarthritis
Abstract Number: 2355

Ixekizumab Provided Rapid Improvement in Key Patient Subgroups with Psoriatic Arthritis: Findings from a Prospective Observational Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
Abstract Number: 2356

Clinical Efficacy in Male and Female Patients With Active Psoriatic Arthritis Treated With Deucravacitinib: A Pooled Analysis of Pivotal Phase 3 Studies
Abstract Number: 2357

Impact of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Active Psoriatic Arthritis: Key Subgroup Analyses in the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].